Provided by Tiger Trade Technology Pte. Ltd.

Repligen

165.18
+0.50000.30%
Post-market: 165.200.0200+0.01%19:30 EDT
Volume:944.56K
Turnover:156.90M
Market Cap:9.30B
PE:226.27
High:168.06
Open:166.72
Low:164.02
Close:164.68
52wk High:188.73
52wk Low:100.99
Shares:56.29M
Float Shares:53.32M
Volume Ratio:0.95
T/O Rate:1.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7300
EPS(LYR):0.8600
ROE:1.99%
ROA:1.40%
PB:4.40
PE(LYR):192.07

Loading ...

Repligen Q2 Revenue Beats Estimates on Higher Orders; Raises Outlook

Reuters
·
Jul 28

Repligen Q2 GAAP EPS Drops 65.38% to $0.09; Revenue Rises 12% to $204 Million

Reuters
·
Jul 28

GUIDANCE: (RGEN) Repligen Expects 2026 Adjusted EPS Range $2.03-$2.09, vs. FactSet Est of $2.00

MT Newswires Live
·
Jul 28

Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate

Benzinga Earnings
·
Jul 28

Repligen Q2 Adjusted EPS USD 0.54 Vs. IBES Estimate USD 0.45

Reuters
·
Jul 28

Repligen Outlook FY Revenue USD 813-835 Million

THOMSON REUTERS
·
Jul 28

Repligen Outlook FY Adjusted EPS USD 2.03-2.09

THOMSON REUTERS
·
Jul 28

RBC Capital Remains a Buy on Repligen (RGEN)

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Community Health (CYH), AnaptysBio (ANAB) and Repligen (RGEN)

TIPRANKS
·
Jul 23

France's Sartorius Stedim Biotech H1 Revenue Rises on Recurring Consumables

Reuters
·
Jul 23

Biolife Solutions Co May be Required to Pay Repligen Termination Fee of $59 Million, if Deal Terminates Under Certain Circumstances- SEC Filing

Reuters
·
Jul 23

Medpace Q2 Revenue Beats Estimates on Backlog Conversion

Reuters
·
Jul 23

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Hold Rating Maintained as Repligen Acquisition Caps BioLife Upside; Price Target Cut to $31 from $33

TIPRANKS
·
Jul 22

Repligen to Acquire BioLife, Expanding Cell Therapy Reach

TIPRANKS
·
Jul 22

Repligen Corp: if Deal Terminated Under Some Circumstances, Biolife May be Required to Pay Repligen a Termination Fee of $59 Mln

THOMSON REUTERS
·
Jul 22

Shares of Biolife up 3.1% Premarket After $1.5 Billion Repligen Buyout

THOMSON REUTERS
·
Jul 22

Repligen Down 2.7%

THOMSON REUTERS
·
Jul 22

Repligen Beefs up Cell Therapy Business with $1.5 Billion Deal for Biolife

Reuters
·
Jul 22

Repligen to Buy Biolife Solutions for About USD 1.5 Billion, Offers USD 31 a Share

Reuters
·
Jul 22